Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03125876
Recruitment Status : Recruiting
First Posted : April 24, 2017
Last Update Posted : January 3, 2019
Sponsor:
Information provided by (Responsible Party):
Sunshine Lake Pharma Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of CT053PTSA in Relapsed/refractory AML patients with FLT3 gene mutation.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia (AML) Drug: CT053PTSA Phase 1

Detailed Description:

It is a multi-center , open-label, dose escalation study conducted in 2 parts. Dose-escalation part: Subjects will receive oral CT053PTSA once daily repeatedly until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days. At least 3 subjects will receive CT053PTSA at each dose (60, 80, 100mg) for determination of Maximum Tolerated Dose(MTD) and Dose Limiting Toxicity (DLT) Dose reduction of CT053PTSA will be considered if study drug-related toxicities are observed in a subject after Cycle 1.

Expansion part:Expansion cohort might be set to further investigate the safety and efficacy of CT053PTSA at or lower MTD dose recommended by dose-escalation part.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 34 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib, Multi-center, Open, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ningetinib (CT053PTSA) in Relapsed / Refractory Acute Myeloid Leukemia (AML)
Actual Study Start Date : November 13, 2017
Estimated Primary Completion Date : January 10, 2019
Estimated Study Completion Date : April 10, 2019


Arm Intervention/treatment
Experimental: CT053PTSA
60mg-100mg
Drug: CT053PTSA
receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
Other Name: Ningetinib




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) [ Time Frame: day 1-28 ]
    Safety and Tolerability assessed through adverse events to determine maximum tolerated dose


Secondary Outcome Measures :
  1. Maximum observed plasma concentration (Cmax) [ Time Frame: On day 1,8,15,22,29 ]
    to assess the pharmacokinetic profile in patients with AML

  2. Time of maximum observed plasma concentration (Tmax) [ Time Frame: On day 1,8,15,22,29 ]
    to assess the pharmacokinetic profile in patients with AML

  3. Area under the plasma concentration time curve [ Time Frame: On day 1,8,15,22,29 ]
    to assess the pharmacokinetic profile in patients with AML

  4. Objective response rate (ORR) [ Time Frame: Through study completion, an expected average of 1.5 year ]
    based on investigator review of radiographic images



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. study population

    a) documented acute myeloid leukemia according to World Health Organization(WHO) criteria(excluding acute promyelocytic leukemia), with Fms-like Tyrosine Kinase 3 (FLT3) gene mutation,refractory/relapsed after common or enhanced chemotherapy c) Recovered from toxicity of previous treatment d) Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 e) Life expectation ≥ 12 weeks

  2. Subjects must have adequate organ function and meeting all of the following laboratory review before enrollment a)blood routine examination: WBC≤2000/mm3 b)liver function: Alanine aminotransferase (ALT) and Aspartate transaminase (AST) ≤2.5×upper limit of normal(ULN); serum bilirubin ≤ 1.5 × ULN c)renal function: Serum creatinine ≤ 1.5×ULN, or the creatinine clearance (CrCl)≥ 60 mL / min calculated by the Cockcroft-Gault formula d) electrolyte: serum potassium≥3.0mmol/L; serum calcium≥2.0 mmol/L e) abnormal serum amylase without symptom≤1.5 × ULN; serum Lipase ≤1.5× ULN f) coagulation function:fibrinogen≥1.0g/L; activated partial thromboplastin time( APTT)≦ULN+10s; prothrombin time(PT)≤ULN+3s g) no obvious organ dysfunction 3)subjects must volunteer to provide evidence of effective diagnosis prior to entry or to accept bone marrow puncture or biopsy for diagnosis, and accept bone marrow puncture or biopsy after treatment to evaluate the efficacy 4) Sign the informed consent

Exclusion Criteria:

Subject meeting any of the following criteria will be excluded.

  1. treatment history

    1. chemotherapy, immunotherapy, radiotherapy, or major surgery within 4 weeks prior to administration;
    2. nitrosourea and mitomycin chemotherapy within 6 weeks prior to the administration;
    3. have taken live vaccines within 4 weeks prior to /or concurrent with the administration;
    4. received FLT3 or Axl inhibitors within 6 weeks prior to the administration;
    5. have received a trial investigational product, or participated in other clinical trials within 4 weeks prior to administration
  2. disease history and surgery history

    a) documented promyelocytic leukemia (t (15; 17) (q22; q11) and / or promyelocytic leukemia(PML)/retinoic acid receptor alpha (RARa) positivity found in the chromosome, variant acute promyelocytic leukemia) b) with myeloid sarcoma or invasion of central nervous system; c) high blood pressure and not well controlled by drug (blood pressure ≥ 140/90 mmHg). Note: Blood pressure before the first administration (mean blood pressure of two measures that 24 hours interval or above ) should be controlled within 140/90 mmHg.

    d) Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) <50%; e) NCI CTCAE 4.03 ≥ 2 grade of arrhythmia, or corrected QT interval(QTc )> 450 ms ; patients with a history of torsion or congenital QT prolonged syndrome; f) any of the illness bellowed within 12 months prior to administration: myocardial infarction, severe or unstable angina, coronary artery bypass graft or peripheral artery bypass surgery, congestive heart failure, cerebrovascular events (including Transient ischemic attack); g) multiple factors that affect oral medication (eg, can not swallow, chronic diarrhea and intestinal obstruction, etc.); h)obvious tendency of gastrointestinal bleeding, including the following cases: local active ulcer lesion, and fecal occult blood test(≥++); melena or hematemesis within 2 months; gastrointestinal bleeding may occurs considered by investigator.

    i)history of immunodeficiency, other acquired or congenital immunodeficiency,history of organ transplantation; j) previous thyroid dysfunction,thyroid function can not be maintained at the normal range even have drug taken.

    k)Human immunodeficiency virus(HIV) positivity l) Hepatitis B surface antigen (HBsAg)positivity, and in the active phase(hepatitis B nucleic acid quantity≥ 1.00 × 103copies / ml); m) Hepatitis C antibody(Anti-HCV) positivity and in the active phase (hepatitis C nucleic acid quantity ≥1.00 × 102copies / ml) n) severe retinopathy or exfoliation judged by the Investigator; o) severe electrolyte imbalance judged by the investigator; p) active infectious disease judged by the investigator; q) other acute or chronic medical or psychological illnesses that are not suitable for clinical trials considered by the investigator or sponsor;

  3. Pregnant or lactating women or female and male with fertility plan. 4)the therapy and/or drug forbidden

    1. taking anticoagulant or vitamin K antagonist such as warfarin, heparin or other similar drugs;
    2. taking other anti-leukemia drugs at the same time, including traditional Chinese medicine (some Chinese medicine can not be used listed in Annex 4);
    3. taking drugs that will prolong QT interval(including Ia and III antiarrhythmic drugs);
    4. patients who need oxygen therapy every day;
    5. long-term use of corticosteroids (local inhalation excluded);

5)others

a) history of Psychotropic drugs abuse and can not drop or the mentally disordered; b) be used to drink grapefruit juice or too much tea, coffee and / or caffeine-containing drink, can not stop during the trial(including Cycle 1 and subsequent treatment period) c) in the vegistrator's judgment, there is a serious accompany disease that jeopardizes patient's safety or interfere with the completion of the study.

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03125876


Contacts
Layout table for location contacts
Contact: Jianxiang Wang, Doctor (086)022-23909067 wangjx@ihcams.ac.cn

Locations
Layout table for location information
China
Hospital of Blood Disease, Chinese Academy of Medical Sciences Recruiting
Tianjin, China
Contact: Jianxiang Wang, MD    (086)022-23909067    wangjx@ihcams.ac.cn   
Principal Investigator: Jianxiang Wang, MD         
Sponsors and Collaborators
Sunshine Lake Pharma Co., Ltd.
Investigators
Layout table for investigator information
Study Chair: Jianxiang Wang, Doctor Hospital of Blood Disease, Chinese Academy of Medical Sciences

Layout table for additonal information
Responsible Party: Sunshine Lake Pharma Co., Ltd.
ClinicalTrials.gov Identifier: NCT03125876     History of Changes
Other Study ID Numbers: PCD-DCT053-16-002
First Posted: April 24, 2017    Key Record Dates
Last Update Posted: January 3, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms